ERBB2 and cancer: In the presence of Herceptin (anti-HER2 antibody), CD16+ NK-92 showed 2-fold enhancement in cytotoxicity against BT474 (HER2+ ductal carcinoma) compared to the parental cells at various NK-92-to-cancer ratios (Figure 7D).